Clinical study on influencing factors to stability of warfarin anticoagulant therapy in patients
with persistent atrial fibrillation Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …

Background Several factors determine the efficacy of warfarin anticoagulation in patients
with non-valvular atrial fibrillation (NVAF). This study aimed to use data from the Chinese …

Objective: To determine the proportion of patients with non-valvular atrial fibrillation (NVAF)
treated with warfarin that achieved a 6‐month period within the target INR range (stability) …

Background: The SAMe-TT2R2 (sex female, age, medical history, treatment, tobacco use,
race) score was developed in patients with atrial fibrillation (AF) on warfarin. The present …

Purpose: Warfarin is the most widely used anticoagulant drug for preventing cardiovascular
diseases after ischemic stroke and thromboembolism related to atrial fibrillation, artificial …

Purpose Although warfarin is an effective oral anticoagulation (OAC) drug to reduce the risk
of thromboembolism in patients with non-valvular atrial fibrillation (NVAF), long term follow …

Background: In the present study, we aimed to evaluate the factors that might be caused by
adequate anticoagulation control in patients treated with warfarin for any reason. Methods …

Objective To analyze the long-term compliance of oral anticoagulant therapy and the
demands of disease management in patient with atrial fibrillation (AF). Methods Inpatients …

Background Warfarin has been considered to provide more stable anticoagulant effect than
acenocoumarol due to its longer half-life. Objective The aim of this SPORTIF-III substudy …

Background Warfarin reduces ischemic stroke risk in atrial fibrillation (AF) but increases
bleeding risk. Novel anticoagulants challenge warfarin as stroke‐preventive therapy for AF …